Description
AS1810722 is an orally active and potent STAT6 inhibitor (IC50:1.9). AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722,a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research